Table 2.
Univariable Analysis: Baseline and Mid‐term Predictors of a Persistent Apparent Healing Condition
| OR | CI 95% | P Value | |
|---|---|---|---|
| Parameters at baseline | |||
| Age (for 1‐year increase) | 0.999 | 0.966 to 1.032 | 0.940 |
| Male sex | 0.646 | 0.232 to 1.797 | 0.403 |
| HF duration (for 1‐month increase) | 0.982 | 0.949 to 1.016 | 0.296 |
| NYHA class (for 1‐class increase) | 1.034 | 0.634 to 1.684 | 0.894 |
| SBP (for 1‐mm Hg increase) | 0.985 | 0.954 to 1.018 | 0.364 |
| LVEF (for 1‐unit increase) | 0.993 | 0.951 to 1.038 | 0.767 |
| LAAI (for 1‐cm2/m2 increase) | 0.964 | 0.848 to 1.083 | 0.533 |
| LVEDDI (for 1‐mm/m2 increase) | 0.997 | 0.983 to 1.011 | 0.683 |
| LVEDVI (for 1‐mL/m2 increase) | 1.016 | 0.918 to 1.124 | 0.761 |
| RFP | 0.835 | 0.284 to 2.454 | 0.744 |
| Significant MR | 0.375 | 0.129 to 1.089 | 0.071 |
| LBBB | 0.640 | 0.195 to 2.100 | 0.461 |
| β‐blockers | 1.231 | 0.396 to 3.825 | 0.720 |
| ACEi/ARBs | 0.403 | 0.108 to 1.495 | 0.174 |
| Parameters at midterm follow‐up | |||
| NYHA class (for 1‐class increase) | 1.354 | 0.435 to 4.220 | 0.601 |
| SBP (for 1‐mm Hg increase) | 0.995 | 0.956 to 1.035 | 0. 799 |
| LVEF (for 1‐unit increase) | 0.948 | 0.881 to 1.021 | 0.158 |
| LAAI (for 1‐cm2/m2 increase) | 0.904 | 0.740 to 1.104 | 0. 321 |
| LVEDDI (for 1‐mm/m2 increase) | 1.071 | 0.924 to 1.241 | 0.644 |
| LVEDVI (for 1‐mL/m2 increase) | 0.994 | 0.963 to 1.025 | 0.686 |
| Significant MR | 0.811 | 0.384 to 1.715 | 0.584 |
| LBBB | 1.094 | 0.252 to 4.740 | 0.905 |
ACEi indicates angiotensin‐converting enzyme inhibitors; ARBs, angiotensin receptor blockers; HF, heart failure; LAAI, indexed left atrial area; LBBB, left bundle‐branch block; LVEDDI, indexed left ventricular end‐diastolic diameter; LVEDVI, indexed left ventricular end‐diastolic volume; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; NYHA, New York Heart Association; OR, odds ratio; RFP, restrictive filling pattern; SBP, systolic blood pressure.